[Alpha Biz= Paul Lee] HLB Group’s stock prices plunged across the board after receiving a second request for supplementary information from the U.S. Food and Drug Administration (FDA) regarding their liver cancer drug.
On Friday (21st), HLB closed at 46,500 KRW, falling by the daily price limit of 29.97%. The stock price plummeted straight to the lower limit right after the opening and failed to recover.
HLB Pharm (-29.92%), HLB Life Science (-29.94%) also closed at the lower limit, along with HLB Panajin (-14.32%), HLB Genex (-15.54%), HLB Global (-18.09%), HLB Science (-14.95%), HLB Innovation (-6.60%), HLB Therapeutics (-7.37%), and HLB Biostep (-14.71%), all experiencing sharp declines.
HLB Group announced the previous night that it had received a request for additional data from the FDA concerning its targeted cancer drug, Rivoceranib.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
